FYB201, a ranibizumab biosimilar, demonstrates equivalent efficacy

COLUMBUS-AMD is a multicenter, parallel-group, 48-week phase III clinical trial that assessed the equivalence of FYB201, a candidate biosimilar for ranibizumab, with reference ranibizumab.
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553